VORI 200 TABLET
VORICONAZOLE USP
What it does
Voriconazole is an antifungal medication used to treat serious fungal infections.
Commonly used for: serious fungal infections, invasive aspergillosis, candidemia
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.
Source this medicineRegistration & product details
Source: Pharmacy and Poisons Board · fetched 2026-01-28 19:49:37 · updated 2026-09-18 02:17:39
Drug Interactions
20Pharmacodynamic Warnings
Voriconazole appears in TABLE 9: Drugs that prolong the QT interval
Severe (6)
Bosentan - increases exposure
Voriconazole is predicted to increase the exposure to endothelin receptor antagonists (bosentan). Avoid.
Clopidogrel - decreases efficacy
Voriconazole is predicted to decrease the efficacy of clopidogrel. Avoid.
Endothelin Receptor Antagonists - increases exposure
Voriconazole is predicted to increase the exposure to endothelin receptor antagonists (bosentan). Avoid.
Voriconazole - decreases concentration
Nirmatrelvir boosted with ritonavir is predicted to decrease the concentration of voriconazole. Avoid.
Voriconazole - decreases exposure
St John's wort moderately decreases the exposure to voriconazole. Avoid.
Voriconazole - decreases exposure
Rifampicin very markedly decreases the exposure to antifungals, azoles (voriconazole). Avoid.
Moderate (6)
Coumarins - increases anticoagulant effect
Voriconazole increases the anticoagulant effect of coumarins. Monitor INR and adjust dose.
Proton Pump Inhibitors - increases exposure
Voriconazoleincreasestheexposuretoprotonpumpinhibitors e (esomeprazole,omeprazole).Adjustdose.oStudy com/codemedicalapps/ cal Applications)
Sulfonylureas - increases concentration
Voriconazole is predicted to increase the concentration of sulfonylureas. Use with caution and adjust dose.
Voriconazole - decreases efficacy
Carbamazepine is predicted to decrease the efficacy of antifungals, azoles (itraconazole, voriconazole) and antifungals, azoles (itraconazole, voriconazole) increase the concentration of carbamazepine
Voriconazole - decreases exposure
Efavirenz moderately decreases the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) slightly increase the exposure to efavirenz. Adjust dose. Also see TABLE 9 p. 1
Voriconazole - decreases exposure
Nevirapine is predicted to decrease the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the exposure to nevirapine. Monitor and adjust dose.
Unknown (8)
Nintedanib - increases exposure
Voriconazoleispredictedtoincreasetheexposureto nintedanib.oTheoretical
Voriconazole - decreases exposure
Fosphenytoin decreases the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the exposure to fosphenytoin. Avoid or adjust voriconazole dose and monitor ph
Voriconazole - decreases exposure
Phenytoin decreases the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the exposure to phenytoin. Avoid or adjust voriconazole dose and monitor phenytoi
Voriconazole - affects exposure
Cobicistatispredictedtoaffecttheexposuretovoriconazole. Avoid.oTheoretical
Voriconazole - decreases exposure
Letermovir slightly decreases the exposure to voriconazole.
Voriconazole - decreases exposure
Lumacaftorispredictedtodecreasetheexposureto antifungals,azoles(itraconazole,ketoconazole,posaconazole, voriconazole).Avoidormonitorefficacy.oTheoretical com/codemedicalapps/ cal Applications)
Voriconazole - affects exposure
HIV-protease inhibitors are predicted to affect the exposure to antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) potentially affect the exposure to HIV-protease inhibitors.
Voriconazole - decreases concentration
Rifabutin decreases the concentration of antifungals, azoles (voriconazole) and antifungals, azoles (voriconazole) increase the concentration of rifabutin. Avoid or adjust voriconazole dose, p. 662.
Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact
About this medicine
Voriconazole is an antifungal medication used to treat serious fungal infections.
What it treats
- serious fungal infections
- invasive aspergillosis
- candidemia
How it works
It works by stopping the growth of fungi that cause infections.
Who it's for
This medication is for adults and children who have severe fungal infections.
Cautions
- • Be cautious if you are taking other medications that can affect heart rhythm.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Voriconazole
BNF-referencedVoriconazole is a triazole antifungal agent primarily used to treat serious fungal infections, particularly those caused by Aspergillus and Candida species. It acts by inhibiting fungal growth through interference with ergosterol synthesis, which is crucial for maintaining fungal cell membrane integrity. Voriconazole exhibits fungistatic activity and is effective against both invasive and resistant strains of fungi.
Indications
- Invasive aspergillosis
- Serious infections caused by Candida species (including C. krusei)
- Infections caused by Scedosporium spp.
- Infections caused by Fusarium spp.
Dosage
Children: Child 15–17 years: Initially 6 mg/kg every 12 hours for 2 doses, then 4 mg/kg every 12 hours; reduced if not tolerated to 3 mg/kg every 12 hours; for max. 6 months.
Adults: Initially 400 mg every 12 hours for 2 doses, then 200 mg every 12 hours, increased if necessary to 300 mg every 12 hours.
Mechanism of action
Voriconazole binds to 14-alpha sterol demethylase (CYP51), inhibiting the demethylation of lanosterol in the ergosterol synthesis pathway. This disruption in ergosterol production leads to compromised fungal cell membrane function, ultimately limiting fungal growth and allowing the host's immune system to eliminate the infection.
Pharmacodynamics
As a fungistatic agent, voriconazole inhibits the growth of various fungi, particularly Aspergillus and Candida species. It is associated with potential hepatotoxicity and photosensitivity reactions, necessitating careful monitoring of liver function during treatment.
Pharmacokinetics
Voriconazole is well-absorbed following oral administration with a bioavailability of approximately 96%. It undergoes extensive hepatic metabolism primarily via CYP2C19, CYP2C9, and CYP3A4. The drug has a half-life ranging from 6 to 12 hours, depending on the individual's metabolic capacity. Voriconazole is predominantly excreted in urine, mainly as metabolites.
Contra-indications
- Acute porphyrias
Adverse effects
- Hepatotoxicity
- Phototoxicity
- Acute kidney injury
- Granulocytosis
- Alopecia
- Anaemia
- Anxiety
- Arrhythmias
- Asthenia
- Bone marrow disorders
- Chest pain
- Chills
- Confusion
- Constipation
- Depression
- Diarrhoea
- Dizziness
- Insomnia
- Leucopenia
- Muscle weakness
Interactions
- Severe: voriconazole + clopidogrel (decreases efficacy)
- Severe: voriconazole + endothelin receptor antagonists (increases exposure)
- Severe: voriconazole + bosentan (increases exposure)
- Severe: nirmatrelvir boosted with ritonavir + voriconazole (decreases concentration)
- Severe: St John's wort + voriconazole (decreases exposure)
- Severe: rifampicin + voriconazole (decreases exposure)
- Moderate: carbamazepine + voriconazole (decreases efficacy)
- Moderate: voriconazole + coumarins (increases anticoagulant effect)
- Moderate: voriconazole + proton pump inhibitors (increases exposure)
Precautions
- Monitor liver function tests regularly during treatment
- Caution in patients with hepatic impairment
- Effective contraception required during treatment
- Monitor for pre-malignant skin lesions and squamous cell carcinoma in case of phototoxicity
Pregnancy
Toxicity in animal studies; manufacturer advises avoiding unless potential benefit outweighs risk.
Breast-feeding
Manufacturer advises avoiding; no information available.
Storage
Store in a cool, dry place away from direct sunlight.
Formulations
- Oral suspension
- Oral solution
- Solution for infusion
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.
Molecular reference: Voriconazole
PubChem CID 71616Molecular formula: C16H14F3N5O
Mechanism of action
Voriconazole is used to treat fungal infections caused by a variety of organisms but including _Aspergillus spp._ and _Candida spp_. Voriconazole is a triazole antifungal exhibiting fungistatic activity against fungal pathogens. Like other triazoles, voriconazole binds to 14-alpha sterol demethylase, also known as CYP51, and inhibits the demethylation of lanosterol as part of the ergosterol synthesis pathway in yeast and other fungi. The lack of sufficient ergosterol disrupts fungal cell membrane function and limits fungal cell growth. With fungal growth limited, the host's immune system is able to clear the invading organism.
Pharmacodynamics
Voriconazole is a fungistatic triazole antifungal used to treat infections by inhibiting fungal growth. It is known to cause hepatotoxic and photosensitivity reactions in some patients.
Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.
This drug in other countries
The same active ingredient registered across other registries we cover - including different brands.